What injection regimen was concluded to be best for Ranibizumab according to the PIER AMD study?

The PIER AMD study found that a monthly injection regimen for Ranibizumab was most effective in maintaining vision and reducing the progression of age-related macular degeneration (AMD). Monthly injections ensured continuous therapeutic exposure to the medication, allowing for the most consistent control of choroidal neovascularization and minimizing the risk of vision loss associated with AMD.

This regimen helped to stabilize patients' conditions, demonstrating a clear benefit in vision outcomes over less frequent dosing schedules. Monthly dosing allows for prompt adjustments in treatment based on the response to therapy, which is critical in managing a progressive disease like AMD. As a result, the monthly injection approach is positioned as standard practice for optimal management of patients suffering from wet AMD, as supported by the findings of the study.